Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.
|ISBN||1868-7083 (Electronic) 1868-7075 (Linking)|
|Authors||Meyer, B.; Clifton, S.; Locke, W.; Luu, P. L.; Du, Q.; Lam, D.; Armstrong, N. J.; Kumar, B.; Deng, N.; Harvey, K.; Swarbrick, A.; Ganju, V.; Clark, S. J.; Pidsley, R.; Stirzaker, C.|
|Responsible Garvan Author||A/Prof Clare Stirzaker|
|Publisher Name||Clinical Epigenetics|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/34922619|